BeiGene News
-
September 17, 2020BeiGene Presents Data at ESMO Virtual Congress 2020 on Phase 3 Trial of Tislelizumab in First-Line Non-Squamous Non-Small Cell Lung Cancer and Phase 2 Trial of Pamiparib in Advanced Ovarian Cancer
BeiGene Presents Data at ESMO Virtual Congress 2020 on Phase 3 Trial of Tislelizumab in First-Line Non-Squamous Non-Small Cell Lung Cancer and Phase 2 Trial of Pamiparib in Advanced Ovarian Cancer
-
September 10, 2020BeiGene to Present at the Morgan Stanley 18th Annual Global Healthcare Conference
BeiGene to Present at the Morgan Stanley 18th Annual Global Healthcare Conference
-
September 9, 2020BeiGene Announces Acceptance and Priority Review by Health Canada of New Drug Submission for BRUKINSA® (zanubrutinib) in Waldenström’s Macroglobulinemia
BeiGene Announces Acceptance and Priority Review by Health Canada of New Drug Submission for BRUKINSA® (zanubrutinib) in Waldenström’s Macroglobulinemia
-
September 4, 2020BeiGene Announces Inclusion of Its Shares in the Shanghai-Hong Kong and Shenzhen-Hong Kong Stock Connect Programs
BeiGene Announces Inclusion of Its Shares in the Shanghai-Hong Kong and Shenzhen-Hong Kong Stock Connect Programs
-
August 27, 2020BeiGene Announces Exclusive License Agreement for Neutralizing COVID-19 Antibodies Developed by Singlomics Biopharmaceuticals
BeiGene Announces Exclusive License Agreement for Neutralizing COVID-19 Antibodies Developed by Singlomics Biopharmaceuticals
-
August 25, 2020BeiGene Appoints Corsee Sanders, Ph.D. to its Board of Directors
BeiGene Appoints Corsee Sanders, Ph.D. to its Board of Directors
- BeiGene Facts
- 2010Founded
- NASDAQ: BGNE
HKEX: 06160Listings - 6Internally Developed
Clinical Candidates - 5Marketed
Products
in China - 1Approved
products
in the U.S. - 4200+Global Team
-
2010
- BeiGene was founded as a research and development company
-
2012
- Began work on an anti-PD-1 antibody and a BTK inhibitor
-
2014
- Started clinical trials of pamiparib and zanubrutinib
-
2016
- Went public on the Nasdaq, with $182 million initial public offering
-
2018
- Established first European office in Switzerland
- 50+ ongoing or planned clinical trials
-
2019
- Received first FDA approval for BRUKINSA™ (zanubrutinib)
- Received first approval for tislelizumab in China
Partnering
Partnerships that Extend Around the Globe
BeiGene is the partner of choice in China for development and commercialization. Read more about our current partnerships and opportunities to build business relationships.
Our Patients
Our Commitment to Patients
At BeiGene we are focused not only on the underserved global cancer patient population, but also on individual people fighting their illnesses.